Monte Rosa Therapeutics

GLUENasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$1.046 B

$12.26 +1.07%

Close of 21 Sept 2026

Revenue

—

Not reported

Earnings

-$38.6M

Loss-making

Shares outstanding

85,313,401

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#47Replimune GroupREPL$1.21B
#48Odyssey TherapeuticsODTX$1.11B
#49Monte Rosa TherapeuticsGLUE$1.05B
#50Attovia TherapeuticsATTO$972.4M
#51SL ScienceSLBT$964.5M

What if Monte Rosa Therapeutics were worth as much as…

Open the what-if tool →

Gold $30.3T

$354,856.96

Per share 28,944× higher

Bitcoin $1.72T

$20,158.66

Per share 1,644× higher

Nvidia $5.48T

$64,232.09

Per share 5,239× higher

Or at a round number

$2.00B $5.00B $10.0B $20.0B

Where these numbers come from

Share counts and financials for Monte Rosa Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.